Shanghai Haohai Biological Technology Co., Ltd. (HKG: 6826)

Market Cap	12.95B
Revenue (ttm)	3.04B
Net Income (ttm)	476.51M
Shares Out	230.28M
EPS (ttm)	1.45
PE Ratio	17.67
Forward PE	11.71
Dividend	0.85 (3.19%)
Ex-Dividend Date	Sep 20, 2024

Volume	84,400
Open	27.10
Previous Close	26.80
Day's Range	26.35 - 27.10
52-Week Range	26.35 - 43.40
Beta	0.74
Analysts	n/a
Price Target	n/a
Earnings Date	Mar 22, 2025

About Shanghai Haohai Biological Technology

Shanghai Haohai Biological Technology Co., Ltd. engages in the research, development, manufacture, and sale of biomedical materials in China, Europe, the United States, and internationally. The company offers ophthalmology products consisting intraocular lens, medical sodium hyaluronate gel, and lubricant eye drop. It also offers sodium hyaluronate injection, medical chitosan, sodium hyaluronate gel, sodium hyaluronate gel, anti adhesion, and burn wound related products. In addition, the company provides injectors, scalpels, and suture needles....

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2007
• Employees: 2,158
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 6826

Financial Performance

In 2023, Shanghai Haohai Biological Technology's revenue was 2.65 billion, an increase of 24.59% compared to the previous year's 2.13 billion. Earnings were 416.12 million, an increase of 130.58%.

Financial numbers in CNY